Testosterone Gel Wolff — Competitive Intelligence Brief

Testosterone Gel Wolff (Testosterone Gel Wolff) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: androgen. Area: Urology.

phase 3 androgen androgen receptor Urology Small molecule

Target snapshot

Testosterone Gel Wolff (Testosterone Gel Wolff) — University Hospital Muenster. Testosterone gel increases testosterone levels in the body.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Testosterone Gel Wolff TARGET	Testosterone Gel Wolff	University Hospital Muenster	phase 3	androgen	androgen receptor
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Winlevi	CLASCOTERONE	Sun Pharma	marketed	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2020-01-01
Nubeqa	darolutamide	Bayer	marketed		androgen receptor (AR)	2019-01-01
APALUTAMIDE	APALUTAMIDE		marketed		Androgen Receptor (AR)	2018-01-01
Erleada	apalutamide	Johnson & Johnson	marketed		Androgen receptor	2018-01-01
Aveed	TESTOSTERONE UNDECANOATE	Marius	marketed	Androgen	Androgen receptor	2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (androgen class)

1. Trust Fertility Clinic · 1 drug in this class
2. University Hospital Muenster · 1 drug in this class